Metropolis

Crisil revises Metropolis outlook to positive, reaffirms 'AA-' rating

Crisil Ratings has revised its outlook on the long-term bank facilities and non-convertible debentures of Metropolis Healthcare Ltd (MHL) to 'positive' from 'stable', while reaffirming its rating at 'Crisil AA-'. The rating agency also reaffirmed its short-term bank facility rating at 'Crisil A1+', according to a note from Crisil Ratings. Crisil said the outlook revision reflects the expected improvement in organic revenue growth, profitability, and cash accruals, along with a meaningful turnaround in its recent acquisition, Core Diagnostics Pvt Ltd. Higher utilisation of the expanded laboratory network, a favourable test mix, and better profitability at Core Diagnostics are expected to support healthy operating margins over the medium term, the agency noted. According to the rating agency, MHL's revenue increased 24 per cent to Rs 1,646 crore in FY26, driven by higher patient volumes and specialised diagnostic and wellness tests under the 'TruHealth' brand. Revenue growth continu

Robust demand, pricing to keep volumes strong for diagnostics sector

Brokerages expect listed diagnostics majors to maintain volume growth through FY27, helped by stable pricing, B2C demand and operating leverage

Metropolis eyes Rs 2,500-cr-plus revenue in 3 years; M&A could add upside

Diagnostics chain plans to sweat existing lab infrastructure, expand company-owned centres from 750 to 1,000

Next phase of growth is about improving utilisation: Surendran Chemmenkotil

In a video-interview with Sohini Das, Surendran Chemmenkotil, Managing Director of Metropolis Healthcare, speaks about the company's FY27 network expansion strategy

Metropolis Healthcare unperturbed by Amazon's diagnostics segment foray

'Amazon's entry is through a partnership with Orange Health. It is more of a distribution through Amazon'

Near-term headwinds may keep Metropolis Healthcare under pressure

The near-term triggers for the stock are the March quarter (Q4FY25) performance and the acquisition of Dr Ahujas' Pathology and Imaging Centre (DAPIC) earlier this week

Metropolis Healthcare expands footprint in North with Dapic acquisition

With its third acquisition in recent times, Metropolis' Ameera Shah said the firm will make another deal this financial year

Metropolis Healthcare to acquire DAPIC for ₹35 crore in all-cash deal

Under the agreement, Metropolis' wholly-owned subsidiary Metropolis Histoxpert Digital Services Pvt Ltd will acquire 100 per cent ownership of DAPIC

Stocks to Watch, Mar 4: IRCTC, IRFC, Adani Green, Metropolis, AGS Transact

Stock market today: The Centre has elevated IRCTC and IRFC from Miniratna I to Navratna status

Metropolis strengthens UP presence with acquisition of Scientific Pathology

This is the second acquisition in the North India market this financial year; share of North market to grow from 8 per cent now to 18 per cent by end of FY26

Core acquisition adds to Metropolis Healthcare's long-term growth plans

Market share gains in the B2C portfolio are visible and Tier III+ markets are likely to contribute to the patient volume growth guidance

Metropolis Healthcare to acquire Core Diagnostics for Rs 247 crore

Diagnostic chain Metropolis Healthcare on Monday said it will acquire Core Diagnostics for Rs 247 crore. The company's board has approved the acquisition of 100 per cent stake in Core Diagnostics from its existing shareholder Core Diagnostics (Mauritius) Pvt Ltd, Metropolis Healthcare said in a regulatory filing. Pursuant to the completion of acquisition, Core Diagnostics will become a wholly owned subsidiary of the company, it added. "This strategic acquisition will enhance Metropolis Healthcare's advanced cancer testing capabilities and strengthen its footprint in northern and eastern India," the diagnostic chain said. By leveraging Core Diagnostics' strong relationships with leading cancer specialists and hospitals in these regions, Metropolis aims to expand its market reach and specialised testing offerings, it added. "With approximately 1.4 million new cancer cases and nearly a million deaths annually in India, there is a critical need for advanced cancer testing nationwide.

Metropolis Healthcare Q3 results: PAT down 24% due to Chennai floods

On a sequential basis, the company exhibited a 5.63 per cent decline in revenue along with PAT, which declined by 23.41 per cent

Metropolis Healthcare eyes 60% revenue from B2C business in next 2-3 years

The diagnostic player has also taken price hikes in the range of 4-5 percent in the last three years

Lots of interest in Metropolis, but we want a strategic fit: MD Ameera Shah

In a Q&A, the promoter and MD of the company talks about how the dynamics are changing in the diagnostics sector post Covid, and outlines her strategy for Metropolis 3.0

Here's why HDFC Securities recommends buying Metropolis, Zensar Tech

Vinay Rajani of HDFC Securities is bullish on Metropolis, Zensar Tech.

Labouring under illusions

The development of Haryana's golden goose has thrived despite reflecting all the worst contradictions of post-liberalisation India

Diagnostic players ride on changes in health insurance to beat slowdown

Metropolis, Dr Lal and Thyrocare are likely to see more gains led by expansion, increasing penetration, preventive testing and government's Ayushman Bharat scheme

Metropolis IPO: Valuations factor in all the positives

Price caps on tests and competitive nature of the sector could test the high valuations

Metropolis' Ameera Shah resists IPO

Metropolis has 1,200 collection centres and a presence in six countries